Answers are grounded in this paper and cite their sources.
#### Key Points Melanoma incidence and mortality are increasing Melanoma is relatively resistant to therapy with standard chemotherapeutic regimens The small molecule inhibitor vemurafenib that targets melanomas with a common and specific mutation (BRAF V600E) has shown promise in the treatment
No takes yet. Share an insight, caveat, or question.
Lacy et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: